Literature DB >> 28291051

Thirty-day Readmission Rates in an HIV-infected Cohort From Rio de Janeiro, Brazil.

Lara E Coelho1, Sayonara R Ribeiro, Andre M Japiassu, Ronaldo I Moreira, Priscila C Lara, Valdilea G Veloso, Beatriz Grinsztejn, Paula M Luz.   

Abstract

BACKGROUND: The 30-day readmission rate is an indicator of the quality of hospital care and transition to the outpatient setting. Recent studies suggest HIV infection might increase the risk of readmission although estimates of 30-day readmission rates are unavailable among HIV-infected individuals living in middle/low-income settings. Additionally, factors that may increase readmission risk in HIV-infected populations are poorly understood.
METHODS: Thirty-day readmission rates were estimated for HIV-infected adults from the Instituto Nacional de Infectologia Evandro Chagas/Fiocruz cohort in Rio de Janeiro, Brazil, from January 2007 to December 2013. Cox regression models were used to evaluate factors associated with the risk of 30-day readmission.
RESULTS: Between January 2007 and December 2013, 3991 patients were followed and 1861 hospitalizations were observed. The estimated 30-day readmission rate was 14% (95% confidence interval: 12.3 to 15.9). Attending a medical visit within 30 days after discharge (adjusted hazard ratio [aHR] = 0.73, P = 0.048) and being hospitalized in more recent calendar years (aHR = 0.89, P = 0.002) reduced the risk of 30-day readmission. In contrast, low CD4 counts (51-200 cells/mm³: aHR = 1.70, P = 0.024 and ≤ 50 cells/mm³: aHR = 2.05, P = 0.003), time since HIV infection diagnosis ≥10 years (aHR = 1.58, P = 0.058), and leaving hospital against medical advice (aHR = 2.67, P = 0.004) increased the risk of 30-day readmission.
CONCLUSIONS: Patients with advanced HIV/AIDS are most at risk of readmission and should be targeted with prevention strategies to reduce this risk. Efforts to reduce discharge against medical advice and to promote early postdischarge medical visit would likely reduce 30-day readmission rates in our population.

Entities:  

Mesh:

Year:  2017        PMID: 28291051      PMCID: PMC5484736          DOI: 10.1097/QAI.0000000000001352

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  40 in total

1.  Thirty-day readmissions--truth and consequences.

Authors:  Karen E Joynt; Ashish K Jha
Journal:  N Engl J Med       Date:  2012-03-28       Impact factor: 91.245

2.  Are all readmissions bad readmissions?

Authors:  Eiran Z Gorodeski; Randall C Starling; Eugene H Blackstone
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  Interventions to reduce 30-day rehospitalization: a systematic review.

Authors:  Luke O Hansen; Robert S Young; Keiki Hinami; Alicia Leung; Mark V Williams
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

4.  Functional impairment and hospital readmission in Medicare seniors.

Authors:  S Ryan Greysen; Irena Stijacic Cenzer; Andrew D Auerbach; Kenneth E Covinsky
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

5.  Rehospitalization for heart failure: predict or prevent?

Authors:  Akshay S Desai; Lynne W Stevenson
Journal:  Circulation       Date:  2012-07-24       Impact factor: 29.690

6.  Incidence and determinants of severe morbidity among HIV-infected patients from Rio de Janeiro, Brazil, 2000-2010.

Authors:  Sayonara R Ribeiro; Paula M Luz; Dayse P Campos; Ronaldo I Moreira; Lara Coelho; André Japiassu; Fernando Bozza; Valdilea G Veloso; Genevieve Chene; Beatriz Grinsztejn
Journal:  Antivir Ther       Date:  2014-01-20

Review 7.  The end of AIDS: HIV infection as a chronic disease.

Authors:  Steven G Deeks; Sharon R Lewin; Diane V Havlir
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

8.  Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease.

Authors:  Gulshan Sharma; Yong-Fang Kuo; Jean L Freeman; Dong D Zhang; James S Goodwin
Journal:  Arch Intern Med       Date:  2010-10-11

9.  Early mortality and cause of deaths in patients using HAART in Brazil and the United States.

Authors:  Beatriz Grinsztejn; Valdilea G Veloso; Ruth K Friedman; Ronaldo I Moreira; Paula M Luz; Dayse P Campos; José H Pilotto; Sandra W Cardoso; Jeanne C Keruly; Richard D Moore
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

10.  HIV disease burden, cost, and length of stay in Portuguese hospitals from 2000 to 2010: a cross-sectional study.

Authors:  Emanuel Catumbela; Alberto Freitas; Fernando Lopes; Maria Del Carmen Torres Mendoza; Carlos Costa; António Sarmento; Altamiro da Costa-Pereira
Journal:  BMC Health Serv Res       Date:  2015-04-08       Impact factor: 2.655

View more
  5 in total

1.  The Importance of Improving the Quality of Care Among HIV/AIDS Hospitalizations in Portugal.

Authors:  Ahmed N Shaaban; Maria Rosario O Martins
Journal:  Front Public Health       Date:  2019-09-13

2.  Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis.

Authors:  Nathan Ford; Gabriela Patten; Ajay Rangaraj; Mary-Ann Davies; Graeme Meintjes; Tom Ellman
Journal:  Lancet HIV       Date:  2022-03       Impact factor: 12.767

3.  CD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort.

Authors:  Kathleen M Akgün; Supriya Krishnan; Adeel A Butt; Cynthia L Gibert; Christopher J Graber; Laurence Huang; Margaret A Pisani; Maria C Rodriguez-Barradas; Guy W Soo Hoo; Amy C Justice; Kristina Crothers; Janet P Tate
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

4.  Risk of Readmission Among HIV Patients in Public Portuguese Hospitals: Longitudinal Multilevel Population-Based Study.

Authors:  Ahmed N Shaaban; Sara S Dias; Zelia Muggli; Bárbara Peleteiro; Maria Rosario O Martins
Journal:  Front Public Health       Date:  2020-02-21

5.  COVID-19: What Is Next for Portugal?

Authors:  Ahmed Nabil Shaaban; Barbara Peleteiro; Maria Rosario O Martins
Journal:  Front Public Health       Date:  2020-08-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.